CA-HOPIN
4.3.2021 13:32:04 CET | Business Wire | Press release
Hopin , a leading virtual events provider, announced today that it has raised $400M in Series C funding co-led by new investors Andreessen Horowitz and General Catalyst, and existing investor IVP, with participation from returning investors Coatue, DFJ Growth, Northzone, Salesforce Ventures and Tiger Global. The funding follows Hopin’s $125 million Series B funding announced in November 2020. Since then, Hopin has added 30,000 customers including Poshmark, American Express, Hewlett Packard, The Financial Times, and YMCA. Since February of last year, Hopin has raised more than $565 million.
Johnny Boufarhat, CEO and Founder of Hopin said: “We are creating a portfolio of products to build the future of live video collaboration and remote community. As we’ve seen, the importance of providing unparalleled virtual and hybrid event experiences has never been greater and this latest funding is a reflection of how critical it is as brands look for ways to connect with people and avenues of growth. To enable this, we are investing more in video innovation, the core medium of digital collaboration. We’re incredibly appreciative of the confidence from our investors who share Hopin’s vision for a better connected world. This is a testament to the dedication of the Hopin team, which works hard to deliver for our customers.”
In addition to the investment, Sriram Krishnan, general partner at Andreessen Horowitz, will join Hopin’s Board of Directors.
“Hopin’s leadership team brings together business, event and software expertise that puts them in a unique position to dramatically transform the way we connect and interact with each other through events,” said Mr. Krishnan. “We believe that Hopin is the leader in this space and couldn’t be more excited to partner with the team on their bold vision.”
Hopin will use this capital to accelerate growth, including scaling its operations, team and platform to meet the demands of its expanding customer base and support its multi-product business. Hopin’s technology is already being used to power the digital component of hybrid experiences in events across Europe, and as announced last week, will soon power new hybrid meeting solutions across the Marriott portfolio of hotels in the United States and Canada. Hopin has scaled from six to more than 400 employees since the beginning of 2020 and grown from a few hundred event creators to more than 85,000 organizations with millions of attendees showing up each month. Hopin will continue investing in the development of its platform technologies in areas such as video and mobile, which are crucial to defining the future of hybrid events and making them a seamless experience. Hopin recently acquired mobile app development company Topi and video streaming company StreamYard, adding StreamYard’s 3.6 million video content creators to its base.
“Johnny and the team have built one of the fastest-growing SaaS companies in history by turning a period of unprecedented disruption into an opportunity to redefine how we gather virtually, in-person, and on the entirely new spectrum of experiences that fall in between," said Quentin Clark, managing director at General Catalyst. "The scale and speed at which they've been able to build Hopin into a global business is impressive. It's also a clear reminder of the significant depth of enterprise and SaaS talent that exists in Europe today."
Hopin Announces New Hires To Support Rapid Growth and Innovation
Hopin is also announcing the appointment of three new executives to its leadership team. Anthony Kennada joins the company as chief marketing officer (CMO), Sarah Manning serves as the vice president of people, and Jonathan Killeen has been named the head of remote.
Mr. Kennada brings extensive GTM experience building the iconic brands of some of the most notable enterprise software companies in the world. He most recently held the role of CMO at Front, the leading customer communication company. Prior to Front, Mr. Kennada was the founding CMO at Gainsight, where he is credited with creating the customer success software category. During his time at Gainsight, he created the Pulse brand of conferences that host over 5,000 attendees at San Francisco’s Moscone Center every year, as well as thousands of attendees at sister conferences in London and Sydney. Mr. Kennada published his marketing playbook at Gainsight with Wiley in 2019 in a book titled Category Creation: How to Build a Brand that Customers, Employees, and Investors Will Love.
Ms. Manning is a strong and proven global HR leader, having worked in large corporations and rapid growth startups. She has successfully partnered with executive leaders on their global people strategies and has led HR teams distributed across four continents. She joins Hopin after serving in senior HR roles at Zendesk and BT.
Mr. Killeen will oversee programs to support Hopin’s fully-remote workforce, developing internal initiatives and systems that focus on building Hopin's remote work culture and optimizing employees’ productivity and workplace engagement. He joins Hopin from Dropbox, where he most recently served as global events program manager & International Workplace Services lead for EMEA & APJ.
“An opportunity to co-author the future of the events industry with event professionals across the globe was an opportunity that I could not pass up,” said Mr. Kennada. “I’m thrilled to partner with Johnny, the amazing Hopin team, and our incredible customers to build a brand that can become a purpose-led and community-enabled platform for the entire industry to collaborate on defining the future.”
About Hopin
Founded in 2019, Hopin enables brands and communities to create all-in-one live video experiences for their audiences. Through its platforms, attendees can learn, interact, and connect with people from anywhere in the world. With Hopin, you can create live virtual and hybrid events that are interactive and immersive. Hopin acquired StreamYard , a leading video streaming studio, in 2020. Hopin is a remote-first company headquartered in London, with employees in 42 countries. Learn more at hopin.com .
About Andreessen Horowitz
Andreessen Horowitz backs bold entrepreneurs who move fast, think big, and are committed to building the next major franchises in technology. Founded by Marc Andreessen and Ben Horowitz, the firm provides entrepreneurs with access to expertise and insights in innovation, executive and technical talent, market intelligence, business development, and marketing and brand-building. Find us in Menlo Park, Calif., and at www.a16z.com .
About General Catalyst
General Catalyst is a venture capital firm that invests in powerful, positive change that endures — for our entrepreneurs, our investors, our people, and society. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond to build companies that withstand the test of time. With offices in San Francisco, Palo Alto, New York City, and Boston, the firm has helped support the growth of businesses such as: Airbnb, Deliveroo, Guild, Gusto, Hubspot, Livongo, Oscar, Samsara, Snap, Stripe, and Warby Parker. For more: www.generalcatalyst.com .
About IVP
Founded in 1980, IVP is one of the premier later-stage venture capital and growth equity firms in the United States. IVP has invested in over 400 companies with 116 IPOs. IVP specializes in venture growth investments, industry rollups, founder liquidity transactions, and select public market investments. IVP investments include such notable companies as AppDynamics (CSCO), Coinbase, Compass, CrowdStrike (CRWD), Datadog (DDOG), Discord, Dropbox (DBX), GitHub (MSFT), Glossier, Grammarly, HashiCorp, Hims & Hers (HIMS), HomeAway (AWAY), Hopin, Klarna, LegalZoom, Looker (GOOGL), Marketo (MKTO), MasterClass, Mindbody (Vista), MuleSoft (CRM), Netflix (NFLX), Personal Capital (Empower), Podium, Rubrik, Slack (WORK), Snap (SNAP), Supercell (Tencent), Tanium, Twitter (TWTR), UiPath, Wise, Yext (YEXT), ZenDesk (ZEN), ZipRecruiter, and Zynga (ZNGA). For more information, visit www.ivp.com or follow IVP on Twitter: @ivp .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005213/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
